Rani Therapeutics Holdings, Inc.
RANI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $172 | $1,028 |
| % Growth | – | -100% | -83.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $172 | $1,028 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $3,221 | $5,505 | $6,570 | $6,810 |
| G&A Expenses | $4,036 | $5,000 | $5,615 | $5,462 |
| SG&A Expenses | $4,036 | $5,000 | $5,615 | $5,462 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $3,714 |
| Operating Expenses | $7,257 | $10,505 | $12,185 | $15,986 |
| Operating Income | -$7,257 | -$10,505 | -$12,013 | -$14,958 |
| % Margin | – | – | -6,984.3% | -1,455.1% |
| Other Income/Exp. Net | -$657 | -$719 | -$725 | -$764 |
| Pre-Tax Income | -$7,914 | -$11,224 | -$12,738 | -$15,722 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,412 | -$6,692 | -$7,264 | -$8,947 |
| % Margin | – | – | -4,223.3% | -870.3% |
| EPS | -0.12 | -0.18 | -0.22 | -0.27 |
| % Growth | 33.3% | 18.2% | 18.5% | – |
| EPS Diluted | -0.12 | -0.18 | -0.22 | -0.27 |
| Weighted Avg Shares Out | 36,542 | 36,542 | 33,440 | 32,660 |
| Weighted Avg Shares Out Dil | 36,542 | 36,542 | 33,440 | 32,660 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $158 | $218 | $360 |
| Interest Expense | $725 | $877 | $943 | $1,124 |
| Depreciation & Amortization | $223 | $240 | $251 | $266 |
| EBITDA | -$6,966 | -$10,107 | -$11,544 | -$14,332 |
| % Margin | – | – | -6,711.6% | -1,394.2% |